Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.
Saved in:
| Title: | Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial. |
|---|---|
| Authors: | Mendell, Jerry R.1,2 (AUTHOR) JMendell@sarepta.com, Muntoni, Francesco3 (AUTHOR), McDonald, Craig M.4 (AUTHOR), Mercuri, Eugenio M.5 (AUTHOR), Ciafaloni, Emma6 (AUTHOR), Komaki, Hirofumi7 (AUTHOR), Leon-Astudillo, Carmen8 (AUTHOR), Nascimento, Andrés9 (AUTHOR), Proud, Crystal10 (AUTHOR), Schara-Schmidt, Ulrike11 (AUTHOR), Veerapandiyan, Aravindhan12 (AUTHOR), Zaidman, Craig M.13 (AUTHOR), Furgerson, Matthew2 (AUTHOR), Ding, Kai2 (AUTHOR), Singh, Preeti2 (AUTHOR), Potter, Rachael2 (AUTHOR), Asher, Damon R.2 (AUTHOR), Murphy, Alexander P.14 (AUTHOR), Reid, Carol14 (AUTHOR), Hooper, Gregory14 (AUTHOR) |
| Source: | Neurology & Therapy. Apr2026, Vol. 15 Issue 2, p545-559. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
